Drug Profile
ESK 1
Alternative Names: ESK1 monoclonal antibody - Eureka Therapeutics/Memorial Sloan Kettering Cancer Center; ESKM; Fc-enhanced TCR-like antibody - Novartis; Intracellular WT 1 targeting anticancer therapeutics - NovartisLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Eureka Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer
- No development reported Leukaemia; Mesothelioma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Leukaemia in USA (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Mesothelioma in USA (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy) in USA (Parenteral)